Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC

Jinmeng Zhang; Dayu Xu; Yue Zhou; Zhengfei Zhu; Xi Yang

doi:10.3389/fonc.2021.676041

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC

Front Oncol. 2021 Jul 30:11:676041. doi: 10.3389/fonc.2021.676041. eCollection 2021.

Authors

Jinmeng Zhang^{1

2}, Dayu Xu^{1

2}, Yue Zhou^{1

2}, Zhengfei Zhu^{1

2}, Xi Yang^{1

2}

Affiliations

¹ Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Abstract

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression in malignant tumor cells and play an important role through complex molecular interactions. Dysregulation of CDK dependent pathways is often found in non-small cell lung cancer, which indicates its vulnerability and can be used in clinical benefit. CDK4/6 inhibitors can prevent tumor cells from entering the G approved 1 and S phases, which have been studied in a series of explorations and brought great clinical effect to patients and encouragement to both physicians and researchers, thereby showing potential as a new therapeutic agent. A series of preclinical and clinical studies have been carried out on CDK4/6 inhibitors in NSCLC, and have been achieved some results, which may become a new potential treatment in the future. This review focuses on the research progress on CDK4/6 inhibitors in NSCLC, particularly the mechanisms of action, drugs, clinical research progress, and future application.

Keywords: NSCLC; cell cycle; cyclin D-dependent kinase 4/6 inhibitor; drugs; therapy.

Publication types

Review